Document:

EXHIBIT 10.59

 

THIS NOTE HAS BEEN ACQUIRED FOR
INVESTMENT AND HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED (THE “SECURITIES ACT”), OR ANY APPLICABLE STATE SECURITIES LAWS.  ADDITIONALLY, THE TRANSFER OF THIS NOTE IS
SUBJECT TO CERTAIN CONDITIONS SPECIFIED IN THE NOTE PURCHASE AGREEMENT DATED AS
OF              
BETWEEN VGX PHARMACEUTICALS, INC.  (THE “COMPANY”)
AND THE SIGNATORY THERETO.  NO TRANSFER
OF THIS NOTE SHALL BE VALID OR EFFECTIVE UNTIL SUCH CONDITIONS HAVE BEEN
FULFILLED.  COPIES OF SUCH AGREEMENT MAY BE
OBTAINED AT NO COST BY WRITTEN REQUEST MADE BY THE HOLDER OF RECORD OF THIS
NOTE TO THE SECRETARY OF THE COMPANY. 
NEITHER THIS NOTE NOR ANY INTEREST HEREIN MAY BE SOLD, TRANSFERRED,
ASSIGNED, PLEDGED, HYPOTHECATED OR OTHERWISE DISPOSED OF UNLESS: (1) A
REGISTRATION STATEMENT WITH RESPECT THERETO IS EFFECTIVE UNDER THE SECURITIES
ACT AND ANY APPLICABLE STATE SECURITIES LAWS; OR (2) THE COMPANY RECEIVES
AN OPINION OF COUNSEL, WHICH OPINION IS SATISFACTORY TO THE COMPANY, THAT
REGISTRATION UNDER SUCH ACT AND APPLICABLE STATE SECURITIES LAWS IS NOT
REQUIRED.

 

AMENDED
AND RESTATED SUBORDINATED PROMISSORY NOTE

 

	
  US $[PRINCIPAL]

  	
   

  	
  Blue Bell,
  Pennsylvania

  
	
   

  	
   

  	
  Original
  Issuance Date:            

  
	
   

  	
   

  	
  Date of
  Amendment and Restatement: November      , 2008

  

 

FOR VALUE
RECEIVED, the undersigned, VGX PHARMACEUTICALS, INC., a Delaware corporation
(the “Borrower”), hereby promises to pay to the order of               ,
(hereinafter, with any subsequent holder, the “Holder”), the principal sum of                     ($###,###) (the “Principal Sum”), together with
interest on the balance of the Principal Sum outstanding at a per annum rate of
five percent (5%), upon the terms set forth below.  Interest shall be calculated on the basis of
the actual number of days elapsed over a 360-day year and shall commence to
accrue on the date hereof.

 

1.             Note
Purchase Agreement.  This amended and
restated subordinated promissory note (this “Note”) amends and restates, and
supersedes in its entirety, that certain convertible subordinated promissory
note that was issued by the Borrower to the Holder on               
(the “Original Note”) pursuant to the terms and conditions of the Note Purchase
Agreement (the “Purchase Agreement”) dated as of                
to which the Borrower and the Holder are parties.  All notices with respect to this Note shall
be made in accordance with Section 5.7 of the Purchase Agreement

 

2.             Maturity.  Unless this Note has been repaid pursuant to Section 6
below, the entire unpaid balance of the Principal Sum outstanding, together
with all accrued, but unpaid, interest and all other fees, costs and charges,
if any, shall be due and payable on the  earliest to occur of:

 

 

(i) [Maturity Date] or (ii) the date of the closing of the transactions
contemplated by that certain Agreement and Plan of Merger dated as of July 7,
2008 among the Company, Inovio Biomedical Corporation and Inovio Acquisition
Corporation, as the same may be amended and/or restated from time to time (the “Maturity
Date”).  No payments of principal or
interest are required hereunder until the Maturity Date.  Upon payment in full of the Principal Sum and
interest payable hereunder, the Holder shall surrender this Note to the
Borrower for cancellation.

 

3.             Payment.  Any payment of principal, interest and all
other fees, costs and charges, if any, shall be in lawful money of the United
States of America by wire transfer of same day funds to the account of the
Holder at such banking institution as the Holder designates or, if requested by
the Holder, by certified or bank cashier’s check payable to the Holder mailed
to the Holder at the address of the Holder as set forth on the records of the
Borrower or such other address as shall be designated in writing by the Holder
to the Borrower.

 

4.             Credits.  The Borrower’s payments will be credited
first to any interest then due, and the remainder to the Principal Sum.  Interest will cease to accrue on any amount
credited to the Principal Sum as of the date any such amount is paid.

 

5.             Financial
Reports.  The Borrower shall furnish
Holder the following financial statements prepared in accordance with generally
accepted accounting principles consistently applied: (i) within thirty
(30) days after the end of each calendar quarter, the Company’s unaudited or if
available, audited balance sheet and statements of income and cash flows for
the quarter just ended; and (ii) as soon as possible after the end of each
fiscal year of the Company, a balance sheet as of the end of its fiscal year
and the related statements of income and cash flows for the fiscal year then
ended, unaudited or if available, audited by an independent certified public
accounting firm; provided, however, that, in the event that the Borrower or any
of its successors or parent entities becomes subject to the financial statement
delivery requirements of the Securities and Exchange Commission, all such
financial statements shall be deliverable by the Borrower promptly after they
are required to be filed with the Securities and Exchange Commission (and not
before such date), notwithstanding anything to the contrary contained in this Section 5.

 

6.             Event
of Default.  Repayment of all
principal and interest under this Note will be accelerated and shall be
immediately due in full in the event of any of the following:

 

(a)           default shall be made
in the payment of the Principal Sum of this Note or any part thereof when and
as the same shall become due and payable, either on the Maturity Date or at a
date fixed by the parties in writing for prepayment or by acceleration or
otherwise and such default continues for a period of 10 days;

 

(b)           default shall be made
in the payment of interest on this Note when and as the same shall become due
and payable and such default continues for a period of 10 days;

 

(c)           the Borrower shall (i) apply
for or consent to the appointment of a receiver, trustee or liquidator of the
Borrower or any of its property, (ii) make a general assignment for the
benefit of creditors, (iii) commence a voluntary case under the federal
bankruptcy laws or file a petition or answer seeking reorganization or an
arrangement with 

 

2

 

creditors to take
advantage of any other bankruptcy, reorganization, insolvency, readjustment of
debt, dissolution or liquidation law or statute, or file an answer admitting
the material allegations of a petition filed against it in any proceeding under
any such law, or (iv) take corporate action for the purpose of effecting
any of the foregoing; or an order, judgment or decree shall be entered, without
the application, approval or consent of the Borrower, by any court of competent
jurisdiction, approving a petition seeking reorganization of the Borrower, or
of all or a substantial part of the assets of the Borrower and such order,
judgment or decree shall continue unstayed and in effect for a period of 60
days;

 

(d)           The Borrower’s failure
to observe and perform any of the material terms, covenants, conditions or
agreements required to be observed and performed by the Borrower under this
Note or the Purchase Agreement, and such failure shall remain unremedied for 30
days after written notice shall have been provided to the Borrower by the
Holder of such default; or

 

(e)           Any representation or
warranty made by the Borrower under this Note or Purchase Agreement or in any other loan document relating to this
transaction, or in any certificate or writing delivered pursuant to any loan
document relating to this transaction, shall be incorrect in any material respect.

 

Nothing
in this Section 7 shall, in any manner, be construed to prohibit or
otherwise affect the rights of the Holder to enforce payment of this Note in
accordance with its terms.

 

7.             Subordination.  All principal and accrued interest on this
Note shall be subordinate in right and time of payment to the payment in full
of all Senior Indebtedness.  Notwithstanding anything to the contrary set
forth in this Note, unless and until the Senior Indebtedness shall have been
indefeasibly satisfied and paid in full in cash and all lending commitments
thereunder have terminated: (a) the Holder may not demand payment of any
of the Principal Sum; (b) no accrued interest on this Note shall be
payable to the Holder; provided, however, that interest on this Note shall
accrue in accordance with the terms of this Note; (c) the indebtedness
evidenced by this Note shall be unsecured; and (d) the holder of this Note
shall not, without the written consent of the holders of the Senior
Indebtedness, take any action with respect to collection or enforcement or
other like action hereunder or exercise any remedies the Holder may have at law
or equity in respect of any amounts owing under this Note, regardless of
whether an Event of Default exists pursuant to Section 7 hereof and regardless
of any remedies provision contained in this Note.  The provisions of this Section 8
shall continue in effect until all amounts under the Senior Indebtedness are
indefeasibly satisfied and paid in full in cash and all lending commitments of
the holders thereof under such Senior Indebtedness shall have terminated,
notwithstanding any delay or failure of such holder in the exercise of any
right or remedy with respect to the Senior Indebtedness.  For purposes
hereof, “Senior Indebtedness” shall mean all present and future obligations due
from the Borrower, its successors and assignees, arising in respect of borrowed
money, or from any bank or other financial institution, which obligations are
secured by any assets of the Borrower, including without limitation, any
principal and all interest thereon and all related fees and expenses.

 

3

 

8.             Transfer
of Note.

 

(a)           Prior to any sale,
assignment, transfer, pledge, hypothecation or other disposition of this Note
or of any legal or beneficial interest herein (a “Transfer”), the Holder shall
give written notice to the Borrower of the Holder’s intention to effect such
Transfer and to comply in all other respects with the provisions of this Section 8.  Each such notice shall contain (a) a
statement setting forth the intention of the Holder’s prospective transferee
with respect to its retention or disposition of this Note, and (b) unless
waived by the Borrower, an opinion of counsel for the Holder, which opinion
shall be reasonably acceptable to the Borrower, addressed to the Borrower as to
the necessity or non-necessity for registration under the Securities Act of
1933, as amended (the “Securities Act”), and applicable state securities laws
in connection with such Transfer and stating the factual and statutory bases
relied upon by counsel.  The following
provisions shall then apply:

 

(1)            If in the opinion of
counsel for the Borrower the proposed Transfer of this Note may be effected
without registration or qualification under the Securities Act and any
applicable state securities laws, then the registered holder of this Note in
accordance with the intended method of disposition specified in the statement
delivered by such holder to the Borrower;

 

(2)           If in the opinion of
counsel for the Borrower the proposed Transfer of this Note may not be effected
without registration under the Securities Act or registration or qualification
under any applicable state securities laws, the registered holder of this Note
shall not be entitled to Transfer all or any portion thereof until the
requisite registration or qualification is effective; and

 

(3)           No Transfers shall be
permitted hereunder unless the transferee agrees in writing to be bound by the
provisions of this Note.

 

(b)           Each instrument issued
upon a Transfer of this Note shall bear the legend set forth in the Purchase
Agreement unless (1) in the opinion of counsel for the Holder, addressed
to the Borrower, the registration of future Transfers is not required by the
applicable provisions of the Securities Act and applicable state securities
laws, (2) the Borrower shall have waived the requirement of such legend or
(3) in the reasonable opinion of counsel to the Borrower, such Transfer
shall have been made in connection with an effective registration statement
filed pursuant to the Securities Act or in compliance with the requirements of Rule 144
or Rule 144A (or any similar or successor rule) promulgated under the
Securities Act, and in compliance with applicable state securities laws.

 

9.             Collection.  Should the indebtedness evidenced by this
Note, or any part hereof, be collected at law or in equity or in bankruptcy,
receivership or other court proceedings, or this Note placed in the hands of
attorneys for collection, the Borrower agrees to pay, in addition to the
balance of the Principal Sum outstanding, together with all accrued, but
unpaid, interest and all other fees, costs and charges, if any, due and payable
hereon, all costs of collection, including reasonable attorneys’ fees, incurred
by the Holder in collecting or enforcing this Note.

 

10.           Demand.  The Borrower hereby waives demand,
presentment, notice, notice of demand, notice for payment, protest and notice
of dishonor.

 

4

 

11.           Waiver.  Holder will not be deemed to waive any of his
rights under this Note unless his waiver is in writing.  No delay or omission by the Holder in
exercising any of his rights will operate as a waiver of his rights.  A waiver in writing on one occasion will not
be construed as a consent to or a waiver of any of the Holder’s right or remedy
on any future occasion.

 

12.           Governing
Law.  This Note shall be governed by
and construed and enforced in accordance with the laws of the Commonwealth of
Pennsylvania and will take effect as an instrument under seal.  Whenever possible, each provision of this
Note will be interpreted in such manner as to be effective and valid under
applicable law, but if any provision of this Note will be prohibited by or
invalid under applicable law, such provision will be ineffective only to the
extent of such prohibition or invalidity, without invalidating the remainder of
such provision or the remaining provisions of this Note.

 

5

 

IN WITNESS WHEREOF, the Company has caused this Note
to be issued this      day of November, 2008.

 

	
   

  	
  VGX PHARMACEUTICALS, INC.

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  By:

  	
   

  
	
   

  	
   

  	
  J. Joseph Kim, Ph.D.

  
	
   

  	
   

  	
  President and Chief
  Executive Officer

  
	
   

  	
   

  	
   

  
	
  The Holder consents to
  the amendment and restatement of the Original Note effected by this Note.

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  Name of Holder
  (please print)

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  Signature of
  Holder

  

 

6EXHIBIT
10.62

 

VIRAL
GENOMIX, INC.

 

EQUITY
COMPENSATION PLAN

 

The
purpose of the Viral Genomix, Inc. Equity Compensation Plan (the “Plan”)
is to provide (i) designated employees of Viral Genomix, Inc. (the
“Company”) and its subsidiaries, (ii) certain consultants and advisors who
perform services for the Company or its subsidiaries and
(iii) non-employee members of the Board of Directors of the Company (the
“Board”) with the opportunity to receive grants of incentive stock options,
nonqualified stock options, and stock awards. 
The Company believes that the Plan will encourage the participants to
contribute materially to the growth of the Company, thereby benefiting the
Company’s stockholders, and will align the economic interests of the
participants with those of the stockholders.

 

1.                                       Administration

 

(a)                                  Committee.  The Plan shall be administered
and interpreted by the Board or by a committee or individual appointed by the
Board (the “Committee”).  After an
initial public offering of the Company’s stock as described in
Section 18(b) (a “Public Offering”), the Plan shall be administered
by a Committee, which may consist of two or more persons who are “outside
directors” as defined under section 162(m) of the Internal Revenue Code of
1986, as amended (the “Code”), and related Treasury regulations and
“non-employee directors” as defined under Rule 16b-3 under the Securities
Exchange Act of 1934, as amended (the “Exchange Act”).  However, the Board may ratify or approve any
grants as it deems appropriate.  If the Board
or an individual administers the Plan, references in the Plan to the
“Committee” shall be deemed to refer to the Board or individual.

 

(b)                                 Committee Authority.  The
Committee shall have the sole authority to (i) determine the individuals
to whom grants shall be made under the Plan, (ii) determine the type, size
and terms of the grants to be made to each such individual,
(iii) determine the time when the grants will be made and the duration of
any applicable exercise or restriction period, including the criteria for
exercisability and the acceleration of exercisability, (iv) amend the
terms of any previously issued grant, and (v) deal with any other matters
arising under the Plan.

 

(c)                                  Committee Determinations.  The
Committee shall have full power and authority to administer and interpret the
Plan, to make factual determinations and to adopt or amend such rules,
regulations, agreements and instruments for implementing the Plan and for the
conduct of its business as it deems necessary or advisable, in its sole
discretion.  The Committee’s
interpretations of the Plan and all determinations made by the Committee
pursuant to the powers vested in it hereunder shall be conclusive and binding
on all persons having any interest in the Plan or in any awards granted
hereunder.  All powers of the Committee
shall be executed in its sole discretion, in the best interest of the Company,
not as a fiduciary, and in keeping with the objectives of the Plan and need not
be uniform as to similarly situated individuals.

 

 

2.                                       Grants

 

Awards
under the Plan may consist of grants of incentive stock options as described in
Section 5 (“Incentive Stock Options”), nonqualified stock options as
described in Section 5 (“Nonqualified Stock Options”) (Incentive Stock
Options and Nonqualified Stock Options are collectively referred to as
“Options”), and stock awards as described in Section 6 (“Stock Awards”)
(hereinafter collectively referred to as “Grants”).  All Grants shall be subject to the terms and
conditions set forth herein and to such other terms and conditions consistent
with this Plan as the Committee deems appropriate and as are specified in
writing by the Committee to the individual in a grant instrument or an
amendment to the grant instrument (the “Grant Instrument”).  The Committee shall approve the form and
provisions of each Grant Instrument. 
Grants under a particular Section of the Plan need not be uniform
as among the grantees.

 

3.                                       Shares Subject to the Plan

 

(a)                                  Shares Authorized. 
Subject to adjustment as described below, the aggregate number of shares
of common stock of the Company (“Company Stock”) that may be issued or
transferred under the Plan is 11,060,000 shares.  After a Public Offering, the maximum
aggregate number of shares of Company Stock that shall be subject to Grants
made under the Plan to any individual during any calendar year shall be 500,000
shares, subject to adjustment as described below.  The shares may be authorized but unissued
shares of Company Stock or reacquired shares of Company Stock, including shares
purchased by the Company on the open market for purposes of the Plan.  If and to the extent Options granted under
the Plan terminate, expire, or are canceled, forfeited, exchanged or
surrendered without having been exercised or if any Stock Awards are forfeited,
the shares subject to such Grants shall again be available for purposes of the
Plan.

 

(b)                                 Adjustments.  If there is any change in the
number or kind of shares of Company Stock outstanding (i) by reason of a
stock dividend, spin-off, recapitalization, stock split, or combination or
exchange of shares, (ii) by reason of a merger, reorganization or
consolidation, (iii) by reason of a reclassification or change in par
value, or (iv) by reason of any other extraordinary or unusual event
affecting the outstanding Company Stock as a class without the Company’s
receipt of consideration, or if the value of outstanding shares of Company
Stock is substantially reduced as a result of a spin-off or the Company’s
payment of an extraordinary dividend or distribution, the maximum number of
shares of Company Stock available for Grants, the maximum number of shares of
Company Stock that any individual participating in the Plan may be granted in
any year, the number of shares covered by outstanding Grants, the kind of
shares issued under the Plan, and the price per share or the applicable market
value of such Grants may be appropriately adjusted by the Committee to reflect
any increase or decrease in the number of, or change in the kind or value of,
issued shares of Company Stock to preclude, to the extent practicable, the
enlargement or dilution of rights and benefits under such Grants; provided,
however, that any fractional shares resulting from such adjustment shall be
eliminated.  Any adjustments determined
by the Committee shall be final, binding and conclusive.

 

2

 

4.                                       Eligibility for Participation

 

(a)                                  Eligible Persons.  All
employees of the Company and its subsidiaries (“Employees”), including
Employees who are officers or members of the Board, and members of the Board
who are not Employees (“Non-Employee Directors”) shall be eligible to
participate in the Plan.  Consultants and
advisors who perform services for the Company or any of its subsidiaries (“Key
Advisors”) shall be eligible to participate in the Plan if the Key Advisors
render bona fide services to the Company or its subsidiaries, the services are
not in connection with the offer and sale of securities in a capital-raising
transaction and the Key Advisors do not directly or indirectly promote or
maintain a market for the Company’s securities.

 

(b)                                 Selection of Grantees.  The
Committee shall select the Employees, Non-Employee Directors and Key Advisors
to receive Grants and shall determine the number of shares of Company Stock
subject to a particular Grant in such manner as the Committee determines.  Employees, Key Advisors and Non-Employee
Directors who receive Grants under this Plan shall hereinafter be referred to
as “Grantees.”

 

5.                                       Granting of Options

 

(a)                                  Number of Shares.  The
Committee shall determine the number of shares of Company Stock that will be
subject to each Grant of Options to Employees, Non-Employee Directors and Key
Advisors.

 

(b)                                 Type of Option and Price.

 

(i)                                     The Committee may grant Incentive Stock
Options that are intended to qualify as “incentive stock options” within the
meaning of section 422 of the Code or Nonqualified Stock Options that are not
intended to qualify or any combination of Incentive Stock Options and
Nonqualified Stock Options, all in accordance with the terms and conditions set
forth herein.  Incentive Stock Options
may be granted only to Employees. 
Nonqualified Stock Options may be granted to Employees, Non-Employee
Directors and Key Advisors.

 

(ii)                                  The purchase price (the “Exercise Price”) of
Company Stock subject to an Option shall be determined by the Committee and may
be equal to, greater than, or less than the Fair Market Value (as defined
below) of a share of Company Stock on the date the Option is granted; provided,
however, that (x) the Exercise Price of an Incentive Stock Option shall be
equal to, or greater than, the Fair Market Value of a share of Company Stock on
the date the Incentive Stock Option is granted and (y) an Incentive Stock
Option may not be granted to an Employee who, at the time of grant, owns stock
possessing more than 10% of the total combined voting power of all classes of
stock of the Company or any parent or subsidiary of the Company, unless the
Exercise Price per share is not less than 110% of the Fair Market Value of
Company Stock on the date of grant.

 

(iii)                               If the Company Stock is publicly traded, then
the Fair Market Value per share shall be determined as follows: (x) if the
principal trading market for the Company Stock is a national securities
exchange or the Nasdaq National Market, the last reported sale price thereof on
the relevant date or (if there were no trades on that date) the latest
preceding date upon which a sale was reported, or (y) if the Company Stock
is not principally traded on such exchange or 

 

3

 

market, the mean between the last reported “bid” and “asked” prices of
Company Stock on the relevant date, as reported on Nasdaq or, if not so
reported, as reported by the National Daily Quotation Bureau, Inc. or as
reported in a customary financial reporting service, as applicable and as the
Committee determines.  If the Company
Stock is not publicly traded or, if publicly traded, is not subject to reported
transactions or “bid” or “asked” quotations as set forth above, the Fair Market
Value per share shall be as determined by the Committee.

 

(c)                                  Option Term.  The Committee shall determine
the term of each Option.  The term of any
Option shall not exceed 10 years from the date of grant.  However, an Incentive Stock Option that is
granted to an Employee who, at the time of grant, owns stock possessing more
than 10% of the total combined voting power of all classes of stock of the
Company, or any parent or subsidiary of the Company, may not have a term that
exceeds five years from the date of grant.

 

(d)                                 Exercisability of Options.

 

(i)                                     Options shall become exercisable in
accordance with such terms and conditions, consistent with the Plan, as may be
determined by the Committee and specified in the Grant Instrument.  The Committee may accelerate the
exercisability of any or all outstanding Options at any time for any reason.

 

(ii)                                  The Committee may provide in a Grant
Instrument that the Grantee may elect to exercise part or all of an Option
before it otherwise has become exercisable. 
Any shares so purchased shall be restricted shares and shall be subject
to a repurchase right in favor of the Company during a specified restriction
period, with the repurchase price equal to the Exercise Price, or such other
restrictions as the Committee deems appropriate.

 

(e)                                  Grants to Non-Exempt Employees. 
Notwithstanding the foregoing, Options granted to persons who are
non-exempt employees under the Fair Labor Standards Act of 1938, as amended, shall
have an Exercise Price not less than 85% of the Fair Market Value of the
Company Stock on the date of grant, and may not be exercisable for at least six
months after the date of grant (except that such Options may become
exercisable, as determined by the Committee, upon the Grantee’s death,
Disability or retirement, or upon a Change in Control or other circumstances
permitted by applicable regulations).

 

(f)                                    Termination of Employment, Disability or
Death.

 

(i)                                     Except as provided below, an Option may only
be exercised while the Grantee is employed by, or providing service to, the
Company as an Employee, Key Advisor or member of the Board.  In the event that a Grantee ceases to be
employed by, or provide service to, the Company for any reason other than Disability,
death, or termination for Cause (as defined below), any Option which is
otherwise exercisable by the Grantee shall terminate unless exercised within 90
days after the date on which the Grantee ceases to be employed by, or provide
service to, the Company (or within such other period of time as may be
specified by the Committee), but in any event no later than the date of
expiration of the Option term.  Except as
otherwise provided by the Committee, any of the Grantee’s Options that are not
otherwise exercisable as of the date on which the Grantee ceases to be employed
by, or provide service to, the Company shall terminate as of such date.

 

4

 

(ii)                                  In the event the Grantee ceases to be
employed by, or provide service to, the Company on account of a termination for
Cause by the Company (as defined below), any Option held by the Grantee shall
terminate as of the date the Grantee ceases to be employed by, or provide
service to, the Company.  In addition, notwithstanding
any other provisions of this Section 5, if the Committee determines that
the Grantee has engaged in conduct that constitutes Cause at any time while the
Grantee is employed by, or providing service to, the Company or after the
Grantee’s termination of employment or service, any Option held by the Grantee
shall immediately terminate and the Grantee shall automatically forfeit all
shares underlying any exercised portion of an Option for which the Company has
not yet delivered the share certificates, upon refund by the Company of the
Exercise Price paid by the Grantee for such shares.  Upon any exercise of an Option, the Company
may withhold delivery of share certificates pending resolution of an inquiry that
could lead to a finding resulting in a forfeiture.

 

(iii)                               In the event the Grantee ceases to be
employed by, or provide service to, the Company because the Grantee is
Disabled, any Option which is otherwise exercisable by the Grantee shall
terminate unless exercised within one year after the date on which the Grantee
ceases to be employed by, or provide service to, the Company (or within such
other period of time as may be specified by the Committee), but in any event no
later than the date of expiration of the Option term.  Except as otherwise provided by the
Committee, any of the Grantee’s Options which are not otherwise exercisable as
of the date on which the Grantee ceases to be employed by, or provide service
to, the Company shall terminate as of such date.

 

(iv)                              If the Grantee dies while employed by, or
providing service to, the Company or within 90 days after the date on which the
Grantee ceases to be employed or provide service on account of a termination
specified in Section 5(f)(i) above (or within such other period of
time as may be specified by the Committee), any Option that is otherwise
exercisable by the Grantee shall terminate unless exercised within one year
after the date on which the Grantee ceases to be employed by, or provide
service to, the Company (or within such other period of time as may be
specified by the Committee), but in any event no later than the date of
expiration of the Option term.  Except as
otherwise provided by the Committee, any of the Grantee’s Options that are not
otherwise exercisable as of the date on which the Grantee ceases to be employed
by, or provide service to, the Company shall terminate as of such date.

 

(v)                                 For purposes of this
Section 5(f) and Section 6:

 

(1)                                  “Company” shall mean the Company and its
parent and subsidiary corporations or other entities, as determined by the
Committee.

 

(2)                                  “Employed by, or provide service to, the
Company” shall mean employment or service as an Employee, Key Advisor or member
of the Board (so that, for purposes of exercising Options and satisfying
conditions with respect to Stock Awards, a Grantee shall not be considered to
have terminated employment or service until the Grantee ceases to be an
Employee, Key Advisor and member of the Board), unless the Committee determines
otherwise.

 

(3)                                   “Disability” shall mean a Grantee’s becoming
disabled within the meaning of section 22(e)(3) of the Code.

 

5

 

(4)                                  “Cause” shall mean, except to the extent
specified otherwise by the Committee, a finding by the Committee of the following:  (i) conviction of Grantee of any felony;
(ii) participation by Grantee in any fraud or act of dishonesty against
the Company; (iii) material violation by Grantee of (a) any contract
between the Company and Grantee or (b) any statutory duty of Grantee to
the Company; (iv) conduct of Grantee that, based upon a good faith and
reasonable factual investigation and determination by the Board, demonstrates
Grantee’s gross unfitness to serve in the capacity as an employee, director or
consultant; or (v) the continued, willful refusal or failure by Grantee to
perform any material duties reasonably requested by the Board; provided,
however, that in the case of conduct described in clauses (iii), (iv) and
(v) hereof, such conduct shall not constitute “Cause” unless:  (a) the Board shall have given Grantee
written notice setting forth with specificity (1) the conduct deemed to
constitute “Cause,” (2) reasonable action that would remedy the
objectionable conduct and (3) a reasonable time (not less than 10 days)
within which Grantee may take such remedial action; and (b) Grantee shall
not have taken such specified remedial action within such specified reasonable
time.

 

(g)                                 Exercise of Options.  A
Grantee may exercise an Option that has become exercisable, in whole or in
part, by delivering a notice of exercise to the Company with payment of the
Exercise Price.  The Grantee shall pay
the Exercise Price for an Option as specified by the Committee (i) in
cash, (ii) with the approval of the Committee, by delivering shares of
Company Stock owned by the Grantee (including Company Stock acquired in
connection with the exercise of an Option, subject to such restrictions as the
Committee deems appropriate) and having a Fair Market Value on the date of
exercise equal to the Exercise Price or by attestation (on a form prescribed by
the Committee) to ownership of shares of Company Stock having a Fair Market
Value on the date of exercise equal to the Exercise Price, (iii) after a
Public Offering, payment through a broker in accordance with procedures
permitted by Regulation T of the Federal Reserve Board, or (iv) by such
other method as the Committee may approve. 
The Committee may authorize loans by the Company to Grantees in
connection with the exercise of an Option, upon such terms and conditions as
the Committee, in its sole discretion, deems appropriate.  Shares of Company Stock used to exercise an
Option shall have been held by the Grantee for the requisite period of time to
avoid adverse accounting consequences to the Company with respect to the
Option.  The Grantee shall pay the
Exercise Price and the amount of any withholding tax due (pursuant to
Section 7) at the time of exercise.

 

(h)                                 Limits on Incentive Stock Options.  Each
Incentive Stock Option shall provide that, if the aggregate Fair Market Value
of the stock on the date of the grant with respect to which Incentive Stock
Options are exercisable for the first time by a Grantee during any calendar
year, under the Plan or any other stock option plan of the Company or a parent
or subsidiary, exceeds $100,000, then the Option, as to the excess, shall be
treated as a Nonqualified Stock Option. 
An Incentive Stock Option shall not be granted to any person who is not
an Employee of the Company or a parent or subsidiary (within the meaning of
section 424(f) of the Code).

 

6

 

6.                                       Stock Awards

 

The
Committee may issue or transfer shares of Company Stock to an Employee,
Non-Employee Director or Key Advisor under a Stock Award, upon such terms as
the Committee deems appropriate.  The
following provisions are applicable to Stock Awards:

 

(a)                                  General Requirements. 
Shares of Company Stock issued or transferred pursuant to Stock Awards
may be issued or transferred for consideration or for no consideration, and
subject to restrictions or no restrictions, as determined by the
Committee.  The Committee may establish
conditions under which restrictions on Stock Awards shall lapse over a period
of time or according to such other criteria as the Committee deems
appropriate.  The period of time during
which the Stock Awards will remain subject to restrictions will be designated
in the Grant Instrument as the “Restriction Period.”

 

(b)                                 Number of Shares.  The
Committee shall determine the number of shares of Company Stock to be issued or
transferred pursuant to a Stock Award and the restrictions applicable to such
shares.

 

(c)                                  Requirement of Employment or Service.  If
the Grantee ceases to be employed by, or provide service to, the Company (as
defined in Section 5(f)) during a period designated in the Grant
Instrument as the Restriction Period, or if other specified conditions are not
met, the Stock Award shall terminate as to all shares covered by the Grant as
to which the restrictions have not lapsed, and those shares of Company Stock
must be immediately returned to the Company. 
The Committee may, however, provide for complete or partial exceptions
to this requirement as it deems appropriate.

 

(d)                                 Restrictions on Transfer and Legend on Stock
Certificate.  During the Restriction Period, a Grantee may
not sell, assign, transfer, pledge or otherwise dispose of the shares of a
Stock Award except to a Successor Grantee under Section 8(a).  Each certificate for a share of a Stock Award
shall contain a legend giving appropriate notice of the restrictions in the
Grant.  The Grantee shall be entitled to
have the legend removed from the stock certificate covering the shares subject
to restrictions when all restrictions on such shares have lapsed.  The Committee may determine that the Company
will not issue certificates for Stock Awards until all restrictions on such
shares have lapsed, or that the Company will retain possession of certificates
for shares of Stock Awards until all restrictions on such shares have lapsed.

 

(e)                                  Right to Vote and to Receive Dividends. 
Unless the Committee determines otherwise, during the Restriction
Period, the Grantee shall have the right to vote shares of Stock Awards and to
receive any dividends or other distributions paid on such shares, subject to
any restrictions deemed appropriate by the Committee.

 

(f)                                    Lapse of Restrictions.  All
restrictions imposed on Stock Awards shall lapse upon the expiration of the
applicable Restriction Period and the satisfaction of all conditions imposed by
the Committee.  The Committee may
determine, as to any or all Stock Awards, that the restrictions shall lapse
without regard to any Restriction Period.

 

7

 

7.                                       Withholding of Taxes

 

(a)                                  Required Withholding.  All
Grants under the Plan shall be subject to applicable federal (including FICA),
state and local tax withholding requirements. 
The Company may require that the Grantee or other person receiving or
exercising Grants pay to the Company the amount of any federal, state or local
taxes that the Company is required to withhold with respect to such Grants, or
the Company may deduct from other wages paid by the Company the amount of any
withholding taxes due with respect to such Grants.

 

(b)                                 Election to Withhold Shares.  If
the Committee so permits, a Grantee may elect to satisfy the Company’s income
tax withholding obligation with respect to Options or Stock Awards paid in
Company Stock by having shares withheld up to an amount that does not exceed
the Grantee’s minimum applicable withholding tax rate for federal (including
FICA), state and local tax liabilities. 
The election must be in a form and manner prescribed by the Committee
and may be subject to the prior approval of the Committee.

 

8.                                       Transferability of Grants

 

(a)                                  Nontransferability of Grants. 
Except as provided below, only the Grantee may exercise rights under a
Grant during the Grantee’s lifetime.  A
Grantee may not transfer those rights except (i) by will or by the laws of
descent and distribution or (ii) with respect to Grants other than
Incentive Stock Options, if permitted in any specific case by the Committee,
pursuant to a domestic relations order or otherwise as permitted by the
Committee.  When a Grantee dies, the
personal representative or other person entitled to succeed to the rights of
the Grantee (“Successor Grantee”) may exercise such rights.  A Successor Grantee must furnish proof
satisfactory to the Company of his or her right to receive the Grant under the
Grantee’s will or under the applicable laws of descent and distribution.

 

(b)                                 Transfer of Nonqualified Stock Options. 
Notwithstanding the foregoing, the Committee may provide, in a Grant
Instrument, that a Grantee may transfer Nonqualified Stock Options to family
members, or one or more trusts or other entities for the benefit of or owned by
family members, consistent with the applicable securities laws, according to
such terms as the Committee may determine; provided that the Grantee receives
no consideration for the transfer of an Option and the transferred Option shall
continue to be subject to the same terms and conditions as were applicable to
the Option immediately before the transfer.

 

9.                                       Right of First Refusal; Repurchase Right

 

(a)                                  Offer.  Prior to a Public Offering, if
at any time an individual desires to sell, encumber, or otherwise dispose of
shares of Company Stock that were issued or distributed to him or her under
this Plan and that are transferable, the individual may do so only pursuant to
a bona fide written offer, and the individual shall first offer the shares to
the Company by giving the Company written notice disclosing: (i) the name
of the proposed transferee of the Company Stock; (ii) the certificate
number and number of shares of Company Stock proposed to be transferred or
encumbered; (iii) the proposed price; (iv) all other terms of the
proposed transfer; and (v) a written copy of the proposed offer.  Within 60 days after receipt of such notice,
the Company shall have the option to purchase all or part of such Company Stock
at the then current Fair Market Value (as defined in Section 5(b)) and may
pay such price in installments over a period not to exceed four years, at the
discretion of the Committee.

 

8

 

(b)                                 Sale.  In the event the Company (or a
stockholder, as described below) does not exercise the option to purchase
Company Stock, as provided above, the individual shall have the right to sell,
encumber, or otherwise dispose of the shares of Company Stock described in
Subsection (a) on the terms of the transfer set forth in the written
notice to the Company, provided such transfer is effected within 15 days after
the expiration of the option period.  If
the transfer is not effected within such period, the Company must again be
given an option to purchase, as provided above.

 

(c)                                  Assignment of Rights.  The
Board, in its sole discretion, may waive the Company’s right of first refusal
and repurchase right under this Section 9. 
If the Company’s right of first refusal or repurchase right is so
waived, the Board may, in its sole discretion, assign such right to the
remaining stockholders of the Company in the same proportion that each
stockholder’s stock ownership bears to the stock ownership of all the
stockholders of the Company, as determined by the Board.  To the extent that a stockholder has been
given such right and does not purchase his or her allotment, the other
stockholders shall have the right to purchase such allotment on the same basis.

 

(d)                                 Purchase by the Company. 
Prior to a Public Offering, if a Grantee ceases to be employed by, or
provide service to, the Company, the Company shall have the right to purchase
all or part of any Company Stock issued or distributed to him or her under this
Plan at its then current Fair Market Value (as defined in Section 5(b))
(or at such other price as may be established in the Grant Instrument);
provided, however, that such repurchase shall be made in accordance with
applicable accounting rules to avoid adverse accounting treatment.

 

(e)                                  Public Offering.  On
and after a Public Offering, the Company shall have no further right to
purchase shares of Company Stock under this Section 9.

 

(f)                                    Stockholders’ Agreement. 
Notwithstanding the provisions of this Section 9, if the Board requires
that a Grantee execute a stockholders’ agreement with respect to any Company
Stock issued or distributed pursuant to this Plan, which contains a right of
first refusal or repurchase right, the provisions of this Section 9 shall
not apply to such Company Stock, unless the Board determines otherwise.

 

10.                                 Change in Control of the Company

 

For
purposes of this Agreement, a “Change in Control” shall be deemed to have
occurred upon:

 

(a)                                  an acquisition subsequent to the date hereof
by any person, entity or group (within the meaning of
Section 13(d)(3) or 14(d)(2) of the Exchange Act) (a “Person”),
of beneficial ownership (within the meaning of Rule 13d-3 promulgated
under the Exchange Act) of 30% or more of either (i) the then outstanding
shares of Company Stock or (ii) the combined voting power of the then
outstanding voting securities of the Company entitled to vote generally in the
election of directors; excluding, however, the following:  (1)  any acquisition directly from the
Company, other than an acquisition by virtue of the exercise of a conversion
privilege unless the security being so converted was itself acquired directly
from the Company; (2) any acquisition by the Company; and (3) any
acquisition by an employee benefit plan (or related trust) sponsored or
maintained by the Company;

 

9

 

(b)                                 a change in the composition of the Board such
that during any period of two consecutive years, individuals who at the
beginning of such period constitute the Board, and any new director (other than
a director designated by a person who has entered into an agreement with the
Company to effect a transaction described in Subsections 10(a), 10(c) or
10(d)) whose election by the Board or nomination for election by the Company’s
stockholders was approved by a vote of at least two-thirds of the directors
then still in office who either were directors at the beginning of the period
or whose election or nomination for election was previously so approved, cease
for any reason to constitute at least a majority of the members thereof;

 

(c)                                  the approval by the stockholders of the
Company of a merger, consolidation, reorganization or similar corporate
transaction, whether or not the Company is the surviving corporation in such transaction,
in which outstanding shares of Company Stock are converted into (i) shares
of stock of another company, other than a conversion into shares of voting
common stock of the successor corporation (or a holding company thereof)
representing 51% or more of the voting power of all capital stock thereof
outstanding immediately after the merger or consolidation or (ii) other
securities (of either the Company or another company) or cash or other
property;

 

(d)                                 the approval by stockholders of the Company
of the issuance of shares of Company Stock in connection with a merger,
consolidation, reorganization or similar corporate transaction in an amount in
excess of 49% of the number of shares of Company Stock outstanding immediately
prior to the consummation of such transaction; or the approval by the
stockholders of the Company of (i) the sale or other disposition of all or
substantially all of the assets of the Company or (ii) a complete
liquidation or dissolution of the Company.

 

11.                                 Consequences of a Change in Control

 

(a)                                  Assumption of Grants.  Upon
a Change in Control where the Company is not the surviving corporation (or
survives only as a subsidiary of another corporation), unless the Committee
determines otherwise, all outstanding Options that are not exercised shall be
assumed by, or replaced with comparable options by the surviving corporation
(or a parent or subsidiary of the surviving corporation), and other outstanding
Grants shall be converted to similar grants of the surviving corporation (or a
parent or subsidiary of the surviving corporation).

 

(b)                                 Other Alternatives. 
Notwithstanding the foregoing, subject to Subsection 11(c) below,
in the event of a Change in Control, the Committee may take any of the
following actions with respect to any or all outstanding Grants: the Committee
may (i) determine that outstanding Options shall automatically accelerate
and become fully exercisable and that the restrictions and conditions on
outstanding Stock Awards shall immediately lapse, (ii) require that Grantees
surrender their outstanding Options in exchange for a payment by the Company,
in cash or Company Stock as determined by the Committee, in an amount equal to
the amount by which the then Fair Market Value of the shares of Company Stock
subject to the Grantee’s unexercised Options exceeds the Exercise Price of the
Options, as applicable or (iii) after giving Grantees an opportunity to
exercise their outstanding Options, terminate any or all unexercised Options at
such time as the Committee deems appropriate. 
Such surrender, termination or settlement shall take place as of the
date of the Change in Control or such other date as the Committee may
specify.  The Committee shall have no
obligation to take any of the foregoing actions, and, in the 

 

10

 

absence
of any such actions, outstanding Grants shall continue in effect according to
their terms (subject to any assumption pursuant to Subsection 11(a)).

 

(c)                                  Limitations.  Notwithstanding anything in
the Plan to the contrary, in the event of a Change in Control, the Committee
shall not have the right to take any actions described in the Plan (including
without limitation actions described in Subsection 11(b), above, that would
make the Change in Control ineligible for pooling of interests accounting
treatment or that would make the Change in Control ineligible for desired tax
treatment if, in the absence of such right, the Change in Control would qualify
for such treatment and the Company intends to use such treatment with respect
to the Change in Control.

 

12.                                 Requirements for Issuance or Transfer of
Shares

 

(a)                                  Stockholders’ Agreement.  The
Committee may require that a Grantee execute a stockholders’ agreement, with
such terms as the Committee deems appropriate, with respect to any Company
Stock issued or distributed pursuant to this Plan.

 

(b)                                 Limitations on Issuance or Transfer of Shares.  No
Company Stock shall be issued or transferred in connection with any Grant
hereunder unless and until all legal requirements applicable to the issuance or
transfer of such Company Stock have been complied with to the satisfaction of
the Committee.  The Committee shall have
the right to condition any Grant made to any Grantee hereunder on such
Grantee’s undertaking in writing to comply with such restrictions on his or her
subsequent disposition of such shares of Company Stock as the Committee shall
deem necessary or advisable, and certificates representing such shares may be
legended to reflect any such restrictions. 
Certificates representing shares of Company Stock issued or transferred
under the Plan will be subject to such stop-transfer orders and other
restrictions as may be required by applicable laws, regulations and
interpretations, including any requirement that a legend be placed thereon.

 

(c)                                  Lock-Up Period.  If
so requested by the Company or any representative of the underwriters (the
“Managing Underwriter”) in connection with any underwritten offering of
securities of the Company under the Securities Act of 1933, as amended (the
“Securities Act”), a Grantee (including any successors or assigns) shall not
sell or otherwise transfer any shares or other securities of the Company during
the 30-day period preceding and the 180-day period following the effective date
of a registration statement of the Company filed under the Securities Act for
such underwriting (or such shorter period as may be requested by the Managing
Underwriter and agreed to by the Company) (the “Market Standoff Period”).  The Company may impose stop-transfer
instructions with respect to securities subject to the foregoing restrictions
until the end of such Market Standoff Period.

 

13.                                 Amendment and Termination of the Plan

 

(a)                                  Amendment.  The Board may amend or
terminate the Plan at any time; provided, however, that the Board shall not
amend the Plan without stockholder approval if such approval 

 

11

 

is
required in order to comply with the Code or other applicable laws, or to
comply with applicable stock exchange requirements.

 

(b)                                 Termination of Plan.  The
Plan shall terminate on the day immediately preceding the tenth anniversary of
its effective date, unless the Plan is terminated earlier by the Board or is
extended by the Board with the approval of the stockholders.

 

(c)                                  Termination and Amendment of Outstanding
Grants.  A termination or amendment of the Plan that
occurs after a Grant is made shall not materially impair the rights of a
Grantee unless the Grantee consents or unless the Committee acts under Section 19(b).  The termination of the Plan shall not impair
the power and authority of the Committee with respect to an outstanding
Grant.  Whether or not the Plan has
terminated, an outstanding Grant may be terminated or amended under
Section 19(b) or may be amended by agreement of the Company and the
Grantee consistent with the Plan.

 

(d)                                 Governing Document.  The
Plan shall be the controlling document. 
No other statements, representations, explanatory materials or examples,
oral or written, may amend the Plan in any manner.  The Plan shall be binding upon and
enforceable against the Company and its successors and assigns.

 

14.                                 Funding of the Plan

 

This Plan shall be
unfunded.  The Company shall not be
required to establish any special or separate fund or to make any other
segregation of assets to assure the payment of any Grants under this Plan.  In no event shall interest be paid or accrued
on any Grant, including unpaid installments of Grants.

 

15.                                 Rights of Participants

 

Nothing
in this Plan shall entitle any Employee, Key Advisor, Non-Employee Director or
other person to any claim or right to be granted a Grant under this Plan.  Neither this Plan nor any action taken
hereunder shall be construed as giving any individual any rights to be retained
by or in the employ of the Company or any other employment rights.

 

16.                                 No Fractional Shares

 

No
fractional shares of Company Stock shall be issued or delivered pursuant to the
Plan or any Grant.  The Committee shall
determine whether cash, other awards or other property shall be issued or paid
in lieu of such fractional shares or whether such fractional shares or any
rights thereto shall be forfeited or otherwise eliminated.

 

12

 

17.                                 Headings

 

Section headings
are for reference only.  In the event of
a conflict between a title and the content of a Section, the content of the
Section shall control.

 

18.                                 Effective Date of the Plan

 

(a)                                  Effective Date. 
Subject to approval by the Company’s stockholders, the Plan shall be
effective on May 15, 2001.

 

(b)                                 Public Offering.  The
provisions of the Plan that refer to a Public Offering, or that refer to, or
are applicable to persons subject to, section 16 of the Exchange Act or section
162(m) of the Code, shall be effective, if at all, upon the initial
registration of the Company Stock under section 12(g) of the Exchange Act,
and shall remain effective thereafter for so long as such stock is so
registered.

 

19.                                 Miscellaneous

 

(a)                                  Grants in Connection with Corporate
Transactions and Otherwise.  Nothing contained in this Plan shall be
construed to (i) limit the right of the Committee to make Grants under
this Plan in connection with the acquisition, by purchase, lease, merger,
consolidation or otherwise, of the business or assets of any corporation, firm
or association, including Grants to employees thereof who become Employees of
the Company, or for other proper corporate purposes, or (ii) limit the
right of the Company to grant stock options or make other awards outside of this
Plan.  Without limiting the foregoing,
the Committee may make a Grant to an employee of another corporation who
becomes an Employee by reason of a corporate merger, consolidation, acquisition
of stock or property, reorganization or liquidation involving the Company or
any of its subsidiaries in substitution for a stock option or stock awards
grant made by such corporation.  The
terms and conditions of the substitute grants may vary from the terms and
conditions required by the Plan and from those of the substituted stock
incentives.  The Committee shall
prescribe the provisions of the substitute grants.

 

(b)                                 Compliance with Law.  The
Plan, the exercise of Options and the obligations of the Company to issue or
transfer shares of Company Stock under Grants shall be subject to all
applicable laws and to approvals by any governmental or regulatory agency as
may be required.  With respect to persons
subject to section 16 of the Exchange Act, after a Public Offering it is the
intent of the Company that the Plan and all transactions under the Plan comply
with all applicable provisions of Rule 16b-3 or its successors under the
Exchange Act.  In addition, it is the
intent of the Company that the Plan and applicable Grants under the Plan comply
with the applicable provisions of section 162(m) of the Code, after a
Public Offering, and section 422 of the Code. 
To the extent that any legal requirement of section 16 of the Exchange
Act or section 162(m) or 422 of the Code as set forth in the Plan ceases
to be required under section 16 of the Exchange Act or section 162(m) or
422 of the Code, that Plan provision shall cease to apply.  The Committee may revoke any Grant if it is
contrary to law or modify a Grant to bring it into compliance with any valid
and mandatory government regulation.  The
Committee may also 

 

13

 

adopt
rules regarding the withholding of taxes on payments to Grantees.  The Committee may, in its sole discretion,
agree to limit its authority under this Section.

 

(c)                                  Employees Subject to Taxation Outside the
United States.  With respect to Grantees who are subject to
taxation in countries other than the United States, the Committee may make
Grants on such terms and conditions as the Committee deems appropriate to comply
with the laws of the applicable countries, and the Committee may create such
procedures, addenda and subplans and make such modifications as may be
necessary or advisable to comply with such laws.

 

(d)                                 Governing Law.  The
validity, construction, interpretation and effect of the Plan and Grant
Instruments issued under the Plan shall be governed and construed by and
determined in accordance with the laws of Delaware, without giving effect to
the conflict of laws provisions thereof.

 

14

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00152-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00152-of-00352.parquet"}]]